merck hansoh news - Search News

Merck reaches weight-loss drug deal worth up to $2 billion

Merck signs deal worth up to $2 billion with China's Hansoh for oral obesity drug

Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's experimental oral obesity drug that works similar to the popular weight-loss treatments Wegovy and Zepbound.

UPI on MSN · 1d

Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named HS-10535. It includes a $112 million licensing rights payment for global sales outside China.

YAHOO!Finance · 2d

Merck moves into obesity with deal for Hansoh’s GLP-1 pill

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.

Seeking Alpha on MSN1d

Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers

Viking Therapeutics (NASDAQ:VKTX) and Structure Therapeutics (NASDAQ:GPCR) were among notable decliners on Wednesday after ...

Pharmabiz1h

Merck inks global license agreement with Hansoh Pharma for investigational oral GLP-1 receptor agonist

Merck, known as MSD outside of the United States and Canada, and Hansoh Pharma, a leading pharmaceutical company in Greater China, announced that they have entered into an exclusive global license ...

FierceBiotech2d

Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

Merck and Hansoh Pharma sign exclusive global license agreement for HS-10535

Merck (MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, announced that they have entered into an exclusive global license agreement ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results